Article Information
- Received January 21, 2012
- Revision received April 26, 2012
- Accepted May 8, 2012
- First published July 11, 2012.
- Version of record published July 11, 2012.
Author Information
- Ruishuang Geng1,
- Sami Melki1,
- Daniel H.-C. Chen1,
- Guilian Tian2,
- David N. Furness3,
- Tomoko Oshima-Takago4,
- Jakob Neef4,
- Tobias Moser4,
- Charles Askew5,
- Geoff Horwitz5,
- Jeffrey R. Holt6,
- Yoshikazu Imanishi2, and
- Kumar N. Alagramam1
- 1Otolaryngology Head and Neck Surgery, University Hospitals Case Medical Center and
- 2Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106,
- 3Institute for Science and Technology in Medicine, School of Life Sciences, Keele University, Staffordshire, ST5 5BG, United Kingdom,
- 4Department of Otolaryngology and Center for Molecular Physiology of the Brain, University of Goettingen, D-37073 Goettingen, Germany,
- 5Department of Neuroscience, University of Virginia School of Medicine, Charlottesville, Virginia 22908, and
- 6Department of Otolaryngology, Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts 02115
Author contributions
Author contributions: R.G., G.T., T.M., J.R.H., Y.I., and K.N.A. designed research; R.G., S.M., D.H.-C.C., G.T., D.N.F., T.O.-T., J.N., T.M., C.A., G.H., and Y.I. performed research; R.G., S.M., D.N.F., J.N., T.M., J.R.H., Y.I., and K.N.A. analyzed data; R.G. and K.N.A. wrote the paper.
Disclosures
- Received January 21, 2012.
- Revision received April 26, 2012.
- Accepted May 8, 2012.
This work was supported by Usher III Initiative (Y.I. and K.N.A.), Elden foundation (Y.I.), National Institutes of Health Grants R01-DC010816 (K.N.A.) and R01-DC05439 (J.R.H.), and Deafness Research UK funds (D.F.), and a grant from the German Research Foundation (T.M.) via the Collaborative Research Center 889, and the state of Lower Saxony (through a “Neurosenses” PhD fellowship to T.O.-T.). We are grateful to Richard Lee and Corrine Thai for their help in the process of generating N48K knock-in mice and Chie Iioka for her help in generating the CLRN1–YFP construct. The monoclonal antibody α5 developed by D. M. Fambrough was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the National Institute of Child Health and Human Development and maintained by The University of Iowa, Department of Biological Sciences (Iowa City, IA).
The authors declare no competing financial interests.
- Correspondence should be addressed to Dr. Kumar Alagramam, Otolaryngology Head and Neck Surgery, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH 44106. kna3{at}case.edu
Online Impact